EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi

Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma Ltd. announced that the UAE Department of Health has granted IND authorization for its PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe endometriosis. The prospective genomics-guided precision medicine study will enroll approximately 84 women across multiple sites in the UAE and aims to identify biomarkers predicting treatment response to the long-acting GnRH antagonist.

EXCLUSIVE: Medicus Pharma Gets UAE Department of Health Approval for Study of Teverelix in Endometriosis; Phase 2a PRECISION-E2 Study Designed to Evaluate Predefined Panel of Genes to Advance Personalized Medicine